Robert Sievers, a former CU Regent, is a professor in the Department of Chemistry and Biochemistry at the University of Colorado Boulder, and former director of CU Boulder’s largest research institute, CIRES. His principle research is now understanding cannabidiol chemistry.
“CBD is worlds different from THC .” CBD is a cannabis compound that some researchers say have significant medical potential, but does not make people feel “stoned.”
“A lot of states, even in the deep south, where there’s been some push-back, have none-the-less passed state laws that allow you to do research with cannabidiol, a non psychoactive, a non addictive constituent, the second most abundant in most cannabis preparations, cannabinoid.”
Recent research into the potential of CBD is looking at its use in treatment of epilepsy and Parkinson’s disease. New research by Dr. Yasmin Hurd at Mt. Sinai looks at the potential of CBD in the treatment of opioid addiction.
Sievers is critical of regulations that create barriers for research into CBD due to the ongoing federal prohibition of cannabis. “There are all kinds of impediments that have been put in the way, especially in the United States, not in the rest of the world, and the rest of the world is racing ahead.”
On November 11th Professor Sievers will give a keynote lecture at an all-day conference at the CU Anschutz Medical Campus in Aurora. Perspectives in Cannabis Research and Education will feature Professor Sievers and other leading cannabis researchers who will discus methods, results and future directions of cannabis research.